VIP-PACAP system in immunity: new insights for multitarget therapy. - Wikidata - wikimedia - TriplyDB

VIP-PACAP system in immunity: new insights for multitarget therapy.

VIP-PACAP system in immunity: new insights for multitarget therapy.

http://www.wikidata.org/entity/Q33343009

about

Role of vasoactive intestinal peptide in osteoarthritis Myalgic Encephalomyelitis: Symptoms and Biomarkers Pituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelae RANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neurons Stress-related programming of autonomic imbalance: role in allergy and asthma.Use of laser microdissection in the investigation of facial motoneuron and neuropil molecular phenotypes after peripheral axotomy The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.Proteomics of rat hypothalamus, hippocampus and pre-frontal/frontal cortex after central administration of the neuropeptide PACAP.VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.Biomarkers predicting a need for intensive treatment in patients with early arthritis Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP.Ameliorative effects of PACAP against cartilage degeneration. Morphological, immunohistochemical and biochemical evidence from in vivo and in vitro models of rat osteoarthritis.PACAP38/PAC1 signaling induces bone marrow-derived cells homing to ischemic brain.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity.Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.Effects of alanyl-glutamine supplementation on the small intestinal mucosa barrier in weaned piglets.Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate.Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor.A new recombinant pituitary adenylate cyclase-activating peptide-derived peptide efficiently promotes glucose uptake and glucose-dependent insulin secretion.Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.Intestinal Microbiota Changes in Mice Lacking Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) - Bifidobacteria Make the Difference Effect of VIP on the balance between cytokines and master regulators of activated helper T cells.Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide.Signalling Alterations in Bones of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Gene Deficient Mice The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis

P2860

Q26739694-7D027259-201F-4F65-AFC0-E5B84D68E7B5 Q26786545-CB5CDD71-9B67-459F-8CA6-867F5C5419A1 Q27345033-5CB9D321-0C62-4A72-92A4-B42AF1C45FFD Q28567751-82600166-AFD4-4984-AB8B-04DEA79B0247 Q30444516-3EE8D12A-49CC-4245-A41F-B9E5802468A2 Q33613350-AF271205-A0DD-4DEE-ABFD-88490CCDA092 Q33643329-01CE11EF-FFE2-4924-B313-9E7838064461 Q33737919-9924CB1D-4C03-4BC4-AF9B-4073C2D56580 Q33936997-EBFDE821-2AA6-44ED-BAAC-939A5CDA8362 Q34788079-7294D264-2FF7-4C5A-84CD-FA885DB043EF Q34982012-E039346B-BC7C-4755-B08C-54FF20E28A15 Q35061216-5FED42EF-24BE-41D7-A1AD-205B5C50AC8A Q35197158-0F4A3436-7807-43FD-B590-D2BCB45CAA8C Q35381453-1D1A27CC-5A34-40EF-812E-B56C574088FC Q35535637-F6A097D6-20A1-4DA5-9A17-9702633F4BD5 Q35768646-F944733E-AF46-48F1-B20B-1872113D0F7F Q36860090-0FD16D59-BA58-4171-8C28-2A1843B611FD Q37074087-C2AA6295-FB83-4E65-B21F-CDE84A202E0C Q37445090-E48CCD1C-F8ED-4ECF-84C7-638431B93C11 Q37447842-F02AE3EA-DE13-40D1-BF47-DA1A7BD3C8DF Q37548872-99E10422-73B6-4BAC-9A24-A2481DADF445 Q38329342-78B6E9F2-AE17-42C7-B40B-45E2DD1EBA3B Q38694548-769ADD81-BAEB-4F05-8703-1841F7E6C0A8 Q39262582-5680A471-6B8A-4A1B-A70B-3B4A5CC19DA5 Q40957920-C54CDA86-6F08-4147-901C-BEC4602B4D17 Q42372827-AAD0896A-EF17-49F0-9FFC-6A52E40EF2CC Q43554142-DDF0F0CE-1767-4B5A-BB08-2771F7D0CE15 Q48120810-582CD064-9937-4A7F-A430-C2D9CBF6C124 Q54385451-2F071323-492D-4551-82BE-9A7C32A517D1 Q58700161-0BE72E0C-2886-4A27-B0F1-7329FE9E7F48 Q58805868-8AC326C8-1CC2-477B-BEF4-2DBC7507FEF0

P2860

VIP-PACAP system in immunity: new insights for multitarget therapy.

http://www.wikidata.org/entity/Q33343009

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

VIP-PACAP system in immunity: new insights for multitarget therapy.

@ast

VIP-PACAP system in immunity: new insights for multitarget therapy.

@en

type

label

VIP-PACAP system in immunity: new insights for multitarget therapy.

@ast

VIP-PACAP system in immunity: new insights for multitarget therapy.

@en

prefLabel

VIP-PACAP system in immunity: new insights for multitarget therapy.

@ast

VIP-PACAP system in immunity: new insights for multitarget therapy.

@en

P1433

Q33343009-695EAAAC-C956-44B9-B6E9-9BFE8FCAF107

P1476

Q33343009-11CFEC5F-EE5D-476B-A545-BCB4C6ABD727

P2093

Q33343009-0369E37C-EA19-460E-A2F9-BC1961D0797F

Q33343009-0786F084-8194-4AD9-9F5E-C95545F3B68B

Q33343009-84C194E1-B900-4655-B80F-B5096F30EB30

Q33343009-A5DE3B08-0C19-4AAD-81AB-79FD5E5C61FA

Q33343009-AD9BD1B1-959D-4618-9574-E11A2150F8E9

Q33343009-F7435C7B-BEFD-420A-B8D8-E98A4EA5E532

P304

Q33343009-BA1C06CB-0BBA-4E21-9D08-B819F961AF0A

P31

Q33343009-3D0D9989-DA75-4BAD-80FF-C007382E37CC

P356

Q33343009-23761AF7-D40D-4FF8-B2E2-3A32D98C41DB

P407

Q33343009-40088F42-686C-4A56-A5E4-30A874621DDA

P478

Q33343009-B0756804-8E74-42DC-9054-AA7BCDE54E9B

P577

Q33343009-D8852670-86A5-4478-8D61-D5AB8D0AB747

P5875

Q33343009-16ECDCD2-9C8E-4DB7-878D-3EC57DDC0107

P698

Q33343009-BBC2A5CC-8CC1-466B-BDF9-8143A458D729

P356

ANNALS.1317.031

P1433

Annals of the New York Academy of Sciences

P1476

VIP-PACAP system in immunity: new insights for multitarget therapy.

@en

P2093

Abad C

http://www.w3.org/2001/XMLSchema#string

Arranz A

http://www.w3.org/2001/XMLSchema#string

Gomariz RP

http://www.w3.org/2001/XMLSchema#string

Juarranz Y

http://www.w3.org/2001/XMLSchema#string

Leceta J

http://www.w3.org/2001/XMLSchema#string

Martinez C

http://www.w3.org/2001/XMLSchema#string

P304

51-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1196/ANNALS.1317.031

http://www.w3.org/2001/XMLSchema#string

P407

P478

1070

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6898988

http://www.w3.org/2001/XMLSchema#string

P698

16888149

http://www.w3.org/2001/XMLSchema#string